A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination with MEDI4736 in Subjects with Advanced Malignancies
A study for patients with advanced cancers using study drugs MEDI0680 and MEDI4736
Sponsor: MedImmune
Enrolling: Male and Female Patients
IRB Number: AAAO9503
U.S. Govt. ID: NCT02118337
Contact: Latoya Stewart: 212-304-5548 / ls3065@cumc.columbia.edu
Additional Study Information: This study is for individuals with advanced cancers. Only patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer (CRC), bladder cancer, ovarian cancer, esophageal cancer, gastric cancer, or renal cell carcinoma will be enrolled. The purpose of the study is to determine the best doses of study drugs MEDI0680 and MEDI4736 and determine how safe and tolerable MEDI0680 and MEDI4736 are when given together in subjects with advanced cancers. This study will also evaluate how much these study drugs are in your blood at various times, whether your immune system become activated following treatment or whether your body produces antibodies against the study drugs, as well as the effect both study drugs have on your cancer.
This study is closed
Do You Qualify?
Is your cancer resistant to or returned after receiving standard therapies, or you were unable to tolerate the treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Latoya Stewart